Compare Enveric Biosciences Inc (ENVB) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs PAGSEG Inc — how do they compare? Enveric Biosciences Inc trades at $1.39 (market cap $5.32M), while PAGSEG Inc trades at $9.19 (market cap $2.57B). The key difference: PAGSEG Inc is far larger — about 483.1× Enveric Biosciences Inc's market cap, and PAGSEG Inc pays a 11.29% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | PAGS | |
|---|---|---|
Market Cap | $5.32M | $2.57B |
Sector | Health | Technology |
52-Week High | $17.40 | $12.00 |
52-Week Low | $1.28 | $7.75 |
Enterprise Value | $408.82K | $10.21B |
Dividend Yield | — | 11.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
PAGS trades at $9.205, down 0.81% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported 2025 revenue of $20.41B and net income of $2.12B, with strong profitability margins and attractive valuation ratios, including a P/E of 6.52. Recent news highlights PagSeguro's potential benefit from Brazil's rate-cutting cycle and its deep valuation discount.
The outlook for PAGS is positive, driven by robust fundamentals, a favorable analyst consensus, and potential tailwinds from monetary policy. Key risks include macroeconomic pressures in Brazil and competitive threats in the financial services sector. The stock presents a value opportunity with upside potential, contingent on execution and economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
